Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment
- 30 January 2003
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 58 (10), 669-675
- https://doi.org/10.1007/s00228-002-0541-7
Abstract
To assess the effect of chronic hepatic impairment on rosuvastatin disposition, pharmacodynamic activity and tolerability.Keywords
This publication has 14 references indexed in Scilit:
- Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjectsBritish Journal of Clinical Pharmacology, 2003
- Liver-Specific Distribution of Rosuvastatin in Rats: Comparison with Pravastatin and SimvastatinDrug Metabolism and Disposition, 2002
- The effect of fluconazole on the pharmacokinetics of rosuvastatinEuropean Journal of Clinical Pharmacology, 2002
- No Effect of Age or Gender on the Pharmacokinetics of Rosuvastatin: A New HMG-CoA Reductase InhibitorThe Journal of Clinical Pharmacology, 2002
- Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass spectrometric detectionJournal of Chromatography B, 2002
- Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-CAtherosclerosis Supplements, 2001
- Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522Atherosclerosis, 2000
- Dosing recommendations in liver diseaseClinical Pharmacology & Therapeutics, 1999
- Methylprednisolone Therapy in Patients with Severe Alcoholic HepatitisAnnals of Internal Medicine, 1989
- Transection of the oesophagus for bleeding oesophageal varicesBritish Journal of Surgery, 1973